

Angelo Viscido

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1683417/publications.pdf>

Version: 2024-02-01

93
papers

3,518
citations

147801

31
h-index

138484

58
g-index

94
all docs

94
docs citations

94
times ranked

3106
citing authors

#	ARTICLE	IF	CITATIONS
1	MR Imaging in Patients with Crohn Disease: Value of T2- versus T1-weighted Gadolinium-enhanced MR Sequences with Use of an Oral Superparamagnetic Contrast Agent. <i>Radiology</i> , 2006, 238, 517-530.	7.3	298
2	Evaluation of Crohn disease activity with magnetic resonance imaging. <i>Abdominal Imaging</i> , 2000, 25, 219-228.	2.0	274
3	Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 747-756.	3.7	159
4	Risk of inflammatory bowel disease attributable to smoking, oral contraception and breastfeeding in Italy: a nationwide case-control study. Cooperative Investigators of the Italian Group for the Study of the Colon and the Rectum (GISC). <i>International Journal of Epidemiology</i> , 1998, 27, 397-404.	1.9	151
5	A New Oral Delivery System for 5-ASA: Preliminary Clinical Findings for MMX. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 421-427.	1.9	133
6	Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. <i>International Journal of Colorectal Disease</i> , 2003, 18, 55-62.	2.2	128
7	Prognostic factors for postoperative recurrence of Crohn's disease. <i>Diseases of the Colon and Rectum</i> , 1996, 39, 335-341.	1.3	121
8	Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 1664-1669.	0.9	113
9	Small Intestine Contrast Ultrasonography. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 146-153.	1.9	104
10	Infliximab in refractory pouchitis complicated by fistulae following ileo-anal pouch for ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 1263-1271.	3.7	90
11	Early versus late surgery for ileo-caecal Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 1303-1312.	3.7	90
12	Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 1413-1417.	3.7	87
13	Two mesalazine regimens in the prevention of the postoperative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 517-523.	3.7	82
14	Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNF \pm therapy. <i>Journal of Clinical Virology</i> , 2008, 43, 180-183.	3.1	77
15	GI distension in severe ulcerative colitis. <i>American Journal of Gastroenterology</i> , 2002, 97, 1169-1175.	0.4	76
16	Infliximab in the treatment of Crohn's disease: Predictors of response in an Italian multicentric open study. <i>Digestive and Liver Disease</i> , 2005, 37, 577-583.	0.9	75
17	Nanotechnology in the treatment of inflammatory bowel diseases. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 903-918.	1.3	71
18	Dietary Factors Modulating Colorectal Carcinogenesis. <i>Nutrients</i> , 2021, 13, 143.	4.1	69

#	ARTICLE	IF	CITATIONS
19	MRI evaluation of Crohn's disease of the small and large bowel with the use of negative superparamagnetic oral contrast agents. <i>Abdominal Imaging</i> , 2002, 27, 384-393.	2.0	57
20	Anti-tissue transglutaminase antibodies in inflammatory bowel disease: new evidence. <i>Clinical Chemistry and Laboratory Medicine</i> , 2004, 42, 1092-7.	2.3	56
21	Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 852-858.	1.3	54
22	Seasonal variations in onset of symptoms in Crohn's disease. <i>Digestive and Liver Disease</i> , 2006, 38, 319-323.	0.9	53
23	Current management of severe ulcerative colitis. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2007, 4, 92-101.	1.7	51
24	Survival and causes of death in Italian patients with ulcerative colitis A GISC nation-wide study. <i>Digestive and Liver Disease</i> , 2001, 33, 686-692.	0.9	46
25	Clinical course of Crohn's disease first diagnosed at surgery for acute abdomen. <i>Digestive and Liver Disease</i> , 2009, 41, 269-276.	0.9	45
26	Subtypes of chronic gastritis in patients with celiac disease before and after gluten-free diet. <i>United European Gastroenterology Journal</i> , 2017, 5, 805-810.	3.8	45
27	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2017, 49, 338-358.	0.9	42
28	Metabolic Alterations in Celiac Disease Occurring after Following a Gluten-Free Diet. <i>Digestion</i> , 2019, 100, 262-268.	2.3	41
29	Is fecal calprotectin an accurate marker in the management of Crohn's disease?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 390-400.	2.8	40
30	Vitamin D in Inflammatory Bowel Diseases. Mechanisms of Action and Therapeutic Implications. <i>Nutrients</i> , 2022, 14, 269.	4.1	39
31	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2019, 51, 632-639.	0.9	36
32	Can Nrf2 Modulate the Development of Intestinal Fibrosis and Cancer in Inflammatory Bowel Disease?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4061.	4.1	33
33	Persistent Iron Deficiency Anemia in Patients with Celiac Disease Despite a Gluten-Free Diet. <i>Nutrients</i> , 2020, 12, 2176.	4.1	33
34	Celiac Disease, Gluten-Free Diet, and Metabolic and Liver Disorders. <i>Nutrients</i> , 2020, 12, 940.	4.1	33
35	Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement. <i>Digestive and Liver Disease</i> , 2005, 37, 407-417.	0.9	32
36	Food Allergies and Ageing. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5580.	4.1	30

#	ARTICLE	IF	CITATIONS
37	Controversial Contribution of Th17/IL-17 Toward the Immune Response in Intestinal Fibrosis. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1299-1306.	2.3	30
38	Sleep disorders related to nutrition and digestive diseases: a neglected clinical condition. <i>International Journal of Medical Sciences</i> , 2021, 18, 593-603.	2.5	30
39	Another paradox in Crohn's disease: New onset of psoriasis in a patient receiving tumor necrosis factor- α antagonist. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 1059-1061.	1.9	29
40	Non-Celiac Gluten Sensitivity among Patients Perceiving Gluten-Related Symptoms. <i>Digestion</i> , 2015, 92, 8-13.	2.3	29
41	The prognostic value of histology in ulcerative colitis in clinical remission with mesalazine. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 749-759.	3.2	27
42	Ferritin as a simple indicator of iron deficiency in anemic IBD patients. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 150-151.	1.9	26
43	Inflammatory Bowel Disease: New Insights into the Interplay between Environmental Factors and PPAR γ . <i>International Journal of Molecular Sciences</i> , 2021, 22, 985.	4.1	25
44	Mucosal features and granulocyte-monocyte-apheresis in steroid-dependent/refractory ulcerative colitis. <i>Digestive and Liver Disease</i> , 2006, 38, 389-394.	0.9	23
45	Mesalazine vanishing time from rectal mucosa following its topical administration. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 102-105.	1.3	21
46	Are Volatile Organic Compounds Accurate Markers in the Assessment of Colorectal Cancer and Inflammatory Bowel Diseases? A Review. <i>Cancers</i> , 2021, 13, 2361.	3.7	21
47	Inflammatory bowel diseases: clinical update of practical guidelines. <i>Nuclear Medicine Communications</i> , 2005, 26, 649-655.	1.1	20
48	Safe use of infliximab for the treatment of fistulizing Crohn's disease during pregnancy within 3 months of conception. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 435-436.	1.9	20
49	Pericarditis after SARS-CoV-2 Infection: Another Pebble in the Mosaic of Long COVID?. <i>Viruses</i> , 2021, 13, 1997.	3.3	20
50	Increased risk of breast cancer in first-degree relatives of Crohn's disease patients An IG-IBD study. <i>Digestive and Liver Disease</i> , 2006, 38, 18-23.	0.9	19
51	Food Allergy Insights: A Changing Landscape. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2020, 68, 8.	2.3	17
52	Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. <i>United European Gastroenterology Journal</i> , 2020, 8, 1228-1235.	3.8	16
53	The Usefulness of Serum Vitamin D Levels in the Assessment of IBD Activity and Response to Biologics. <i>Nutrients</i> , 2021, 13, 323.	4.1	15
54	Biological agents in the treatment of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 1579-1590.	3.7	14

#	ARTICLE	IF	CITATIONS
55	Efficacy of conventional immunosuppressive drugs in IBD. <i>Digestive and Liver Disease</i> , 2004, 36, 766-780.	0.9	13
56	Predictive factors of clinical response in steroid-refractory ulcerative colitis treated with granulocyte-monocyte apheresis. <i>World Journal of Gastroenterology</i> , 2011, 17, 1831.	3.3	12
57	Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-9.	1.5	12
58	<p>Has infliximab influenced the course and prognosis of acute severe ulcerative colitis</p>. <i>Biologics: Targets and Therapy</i> , 2019, Volume 13, 23-31.	3.2	12
59	Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis. <i>BMC Gastroenterology</i> , 2022, 22, 92.	2.0	12
60	Successful treatment with infliximab of refractory pyoderma gangrenosum in 2 patients with inflammatory bowel diseases. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 1317-1319.	1.9	9
61	Serum transglutaminase antibodies do not always detect the persistent villous atrophy in patients with celiac disease on a gluten-free diet. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e650-e655.	1.6	8
62	Effects of Exercise Training on Delaying Disease Progression in Patients with Chronic Kidney Disease: a Review of the Literature. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 333-341.	0.8	8
63	Mesalazine treatment in organotypic culture of celiac patients: Comparative study with gluten free diet. <i>Journal of Cellular Physiology</i> , 2018, 233, 4383-4390.	4.1	7
64	Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e134-e136.	1.9	6
65	Magnetic resonance enterography (MRE) and ultrasonography (US) in the study of the small bowel in Crohn's disease: state of the art and review of the literature. <i>Acta Biomedica</i> , 2019, 90, 38-50.	0.3	6
66	Non-steroidal anti-inflammatory drugs and acetylsalicylic acid increase the risk of complications of diverticular disease: a meta-analysis of caseâ€control and cohort studies. <i>International Journal of Colorectal Disease</i> , 2022, 37, 521-529.	2.2	6
67	Two synchronous adenocarcinomas of the small bowel in a patient with undiagnosed Crohn's disease of the terminal ileum. <i>International Journal of Colorectal Disease</i> , 2006, 21, 388-391.	2.2	5
68	Mastocytic enterocolitis: Increase of mast cells in the gastrointestinal tract of patients with chronic diarrhea. <i>Gastroenterolog&A Y Hepatolog&A</i> , 2017, 40, 467-470.	0.5	5
69	Risk of colonoscopic post-polypectomy bleeding in patients on single antiplatelet therapy: systematic review with meta-analysis. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 2258-2270.	2.4	5
70	Association of Colonic Diverticula with Colorectal Adenomas and Cancer. <i>Medicina (Lithuania)</i> , 2021, 57, 108.	2.0	4
71	Fecal Lactoferrin and Other Putative Fecal Biomarkers in Crohn&TM's Disease: Do They Still Have a Potential Clinical Role?. <i>Digestion</i> , 2021, 102, 833-844.	2.3	4
72	Development of Fistulae in Ileo-Anal Pouch does not Necessarily Indicate Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2004, 99, 2066-2067.	0.4	3

#	ARTICLE	IF	CITATIONS
73	Duodenal lymphocytosis in functional dyspepsia. Arab Journal of Gastroenterology, 2019, 20, 91-94.	0.9	3
74	Could Pirfenidone Also be Effective in Treating Intestinal Fibrosis?. Cells, 2020, 9, 1762.	4.1	3
75	Lymphocytic gastritis and celiac disease. Polish Journal of Pathology, 2021, 72, 87-88.	0.3	2
76	Wegener's granulomatosis and retroperitoneal fibrosis: a case report and review of the literature. Italian Journal of Medicine, 2019, 13, 109-115.	0.3	1
77	Topical Aminosalicylates and Histologic Healing in Ulcerative Colitis. American Journal of Gastroenterology, 2019, 114, 1922-1923.	0.4	1
78	Use of biosimilars in inflammatory bowel diseases: A survey among the clinicians members of the Italian Group for the Study of Inflammatory Bowel Disease (IGIBD). Digestive and Liver Disease, 2020, 52, 928-930.	0.9	1
79	El impacto de la dieta libre de gluten en pacientes con enfermedad celíaca, sensibilidad al gluten no celíaca y controles asintomáticos. La necesidad de alimentos libres de gluten más sanos. Revista De Gastroenterología De México, 2020, 85, 373-374.	0.2	1
80	The Role on Endoscopy in Alcohol-Related Diseases. Reviews on Recent Clinical Trials, 2016, 11, 196-200.	0.8	1
81	Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease.. Revista Espanola De Enfermedades Digestivas, 2020, 113, 154-155.	0.3	1
82	Risk of surgery and the Vienna classification of Crohn's disease. Gastroenterology, 2000, 118, A583.	1.3	0
83	Magnetic resonance imaging (MRI) in the management of patients with Crohn's disease (CD): An index of effectiveness in course of therapy with anti-TNF antibodies. Gastroenterology, 2000, 118, A321.	1.3	0
84	Predictive risk factors for surgery in Crohn's disease. Gastroenterology, 2003, 124, A204.	1.3	0
85	Laboratory diagnosis of iron deficiency in inflammatory bowel disease. Gastroenterology, 2003, 124, A203.	1.3	0
86	Diagnostic accuracy of small intestine contrast ultrasonography (Sicus) in the assessment of small intestinal lesions in Crohn's disease. Gastroenterology, 2003, 124, A200.	1.3	0
87	Infliximab and quality of life in steroid-dependent Crohn's disease. Digestive and Liver Disease, 2004, 36, 557-558.	0.9	0
88	Quality of Life in Steroid-Dependent/Refractory Ulcerative Colitis After Granulocyteapheresis. Inflammatory Bowel Diseases, 2006, 12, S27.	1.9	0
89	Association between Corrected QT Interval and C-Reactive Protein in Patients with Inflammatory Bowel Diseases. Medicina (Lithuania), 2020, 56, 382.	2.0	0
90	Topography, morphology, and etiology of lymphocytic gastritis: a focus on celiac disease. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 165-166.	2.8	0

#	ARTICLE	IF	CITATIONS
91	Non-medical Switching of Infliximab to CT-P13 Biosimilar in Inflammatory Bowel Disease: A Focus on the Definition of "Non-medical Switch". Digestive Diseases and Sciences, 2020, 65, 2737-2738.	2.3	0
92	Secondary hemophagocytic lymphohistiocytosis: a case report. Acta Biomedica, 2021, 92, e2021060.	0.3	0
93	GI distension in severe ulcerative colitis. American Journal of Gastroenterology, 2002, 97, 1169-1175.	0.4	0